Synonyms: Artrodar® | Fisiodar®
diacerein is an approved drug
Compound class:
Synthetic organic
Comment: Diacerein is a prodrug which is metabolized to rhein. It has anti-inflammatory activity via antagonism of the interleukin-1 receptor. It is an anthraquinone type compound and growth-inhibitory effects of diacerein have been shown against various drug-resistant staphylococcal strains [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Diacerein is not approved by the FDA or the EMA, but has been granted marketing authorisation by regulatory agencies in a number of countries. It is used to treat osteoarthritis, but this use is limited by its propensity to cause severe diarrhea. Clinical trials in other conditions are ongoing. Orphan designation for the treatment of epidermolysis bullosa was issued by the EMA in May 2019 [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04351100 | Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients | Observational | Chulalongkorn University | ||
NCT03389308 | Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex | Phase 2 Interventional | Castle Creek Pharmaceuticals, LLC | ||
NCT02242149 | Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects | Phase 3 Interventional | Universidade Federal do Rio de Janeiro | ||
NCT02060552 | Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels | Phase 4 Interventional | Tongji Hospital |